Psoriasiform drug eruption induced by anti-tuberculosis medication: Potential role of plasmacytoid dendritic cells

Acta Dermato-Venereologica

Volumn 90, Issue 3, 2010, Pages 305-306

  Park, Jae Jeong ^a   Choi, Yoo Duk ^a   Lee, Jee Bum ^a   Kim, Seong Jin ^a   Lee, Seung Chul ^a   Won, Young Ho ^a   Yun, Sook Jung ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; DOXAZOSIN MESYLATE; ETHAMBUTOL; ISONIAZID; PYRIDOXINE; RIFAMPICIN; TAMSULOSIN;

AGED; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LETTER; MALE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PSORIASIS; SKIN BIOPSY; TUBERCULOSIS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ANTITUBERCULAR AGENTS; BIOPSY; DENDRITIC CELLS; DRUG ERUPTIONS; ERYTHEMA; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PRURITUS; PSORIASIS; SKIN; STEROIDS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 77953418625     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0827     Document Type: Letter

References (13)

1. Justiniano H, Berlingeri-Ramos AC, Sánchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008; 30: 352-369.
2. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-231.
3. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000; 1: 159-165.
4. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol 2006; 25: 1-11.
5. Sehgal VN, Dogra S, Srivastava G, Aggarwal AK. Psoriasiform dermatoses. Indian J Dermatol Venereol Leprol 2008; 74: 94-99.
6. Vieira DE, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J Bras Pneumol 2008; 34: 1049-1055.
7. Kurokawa I, Nakahigashi Y, Teramachi M. Erythema multiforme-type drug eruption due to ethambutol with eosinophilia and liver dysfunction. Int J Antimicrob Agents 2003; 21: 596-597.
8. Grossman ME, Warren K, Mady A, Satra HK. Lichenoid eruption associated with ethambutol. J Am Acad Dermatol 1995; 33: 675-676.
9. Bovenschen HJ, Kop EN, Van de Kerkhof PC, Seyger MM. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatolog Treat 2006; 17: 381-383.
10. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
11. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001.
12. Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009; 129: 1088-1099.
13. Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol 2009; 129: 315-319.